Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

UNCY - Unicycive Therapeutics, Inc. Stock Price, Fair Value and News

$0.58-0.01 (-1.69%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

UNCY Price Action

Last 7 days

5.4%

Last 30 days

9.3%

Last 90 days

-20.3%

Trailing 12 Months

-58.7%

UNCY RSI Chart

JunJulAugSepOctNovDec2025FebMar0102030405060708090

UNCY Valuation

Market Cap

61.2M

Price/Earnings (Trailing)

-2.66

Price/Sales (Trailing)

73.81

Price/Free Cashflow

-2.31

UNCY Price/Sales (Trailing)

2023AprJulOct2024AprJulOct020406080100

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

UNCY Fundamentals

UNCY Revenue

Revenue (TTM)

675.0K

Oct2023AprJulOct2024AprJul700K750K800K850K900K950K

UNCY Earnings

Earnings (TTM)

-23.0M

Earnings Growth (Yr)

5.47%

Earnings Growth (Qtr)

-141.56%

2021202220232024-40M-30M-20M-10M0

UNCY Profitability

Return on Equity

-82.59%

Return on Assets

-59.63%

Free Cashflow Yield

-43.3%

UNCY Investor Care

Shares Dilution (1Y)

198.66%

Diluted EPS (TTM)

-0.83

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
2023AprJulOct700K750K800K850K900K950K
Net sales
YearQ1Q2Q3Q4
20240000
2023882.0K813.0K744.0K675.0K
2022000951.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
 CEO
 WEBSITEhttps://unicycive.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

Unicycive Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Unicycive Therapeutics, Inc.? What does UNCY stand for in stocks?

UNCY is the stock ticker symbol of Unicycive Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Unicycive Therapeutics, Inc. (UNCY)?

As of Wed Mar 12 2025, market cap of Unicycive Therapeutics, Inc. is 61.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of UNCY stock?

You can check UNCY's fair value in chart for subscribers.

Is Unicycive Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether UNCY is over valued or under valued. Whether Unicycive Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Unicycive Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for UNCY.

What is Unicycive Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 12 2025, UNCY's PE ratio (Price to Earnings) is -2.66 and Price to Sales (PS) ratio is 73.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. UNCY PE ratio will change depending on the future growth rate expectations of investors.